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ABSTRACT
Copper-ionophores that elevate intracellular bioavailable copper display 
significant therapeutic utility against prostate cancer cells in vitro and in TRAMP 
(Transgenic Adenocarcinoma of Mouse Prostate) mice. However, the pharmacological 
basis for their anticancer activity remains unclear, despite impending clinical trails. 
Herein we show that intracellular copper levels in prostate cancer, evaluated in vitro 
and across disease progression in TRAMP mice, were not correlative with copper-
ionophore activity and mirrored the normal levels observed in patient prostatectomy 
tissues (Gleason Score 7 & 9). TRAMP adenocarcinoma cells harbored markedly 
elevated oxidative stress and diminished glutathione (GSH)-mediated antioxidant 
capacity, which together conferred selective sensitivity to prooxidant ionophoric 
copper. Copper-ionophore treatments [CuII(gtsm), disulfiram & clioquinol] generated 
toxic levels of reactive oxygen species (ROS) in TRAMP adenocarcinoma cells, but not 
in normal mouse prostate epithelial cells (PrECs). Our results provide a basis for the 
pharmacological activity of copper-ionophores and suggest they are amendable for 
treatment of patients with prostate cancer. Additionally, recent in vitro and mouse 
xenograft studies have suggested an increased copper requirement by prostate cancer 
cells. We demonstrated that prostate adenocarcinoma development in TRAMP mice 
requires a functional supply of copper and is significantly impeded by altered systemic 
copper distribution. The presence of a mutant copper-transporting Atp7b protein 
(tx mutation: A4066G/Met1356Val) in TRAMP mice changed copper-integration into 
serum and caused a remarkable reduction in prostate cancer burden (64% reduction) 
and disease severity (grade), abrogating adenocarcinoma development. Implications 
for current clinical trials are discussed.
INTRODUCTION
Prostate cancer is a major cause of morbidity and 
mortality among elderly men worldwide and is rapidly 
becoming more prevalent as life expectancy increases 
[1, 2]. Early detection is paramount, and treatment 
regimes are disease stage-dependent and can include 
combinations of radical prostatectomy, brachytherapy 
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(implanted radioactive seeds) and androgen deprivation 
(hormone therapy). Unfortunately, these therapies 
are often not curative and the majority of patients 
relapse into castration-resistant (hormone-refractory) 
disease. While attention is still focused primarily 
on developing androgen deprivation, a number of 
additional pharmacological targets have emerged (e.g. 
protein tyrosine kinases [3], mitochondrial metabolism 
[4] or prostate-specific membrane antigen [5]), 
highlighting the growing consensus that alternative 
therapies for prostate cancer are needed [6]. We recently 
established that prostate cancer cells, both in vitro and 
in the orthotopic TRAMP mouse model, are remarkably 
sensitive to a family of lipophilic compounds 
categorized as copper-ionophores [7–9]. Ionophores 
bind and transport specific metal(s) indiscriminately into 
cells, often allowing the ions to become bioavailable 
(exchangeable) [8, 10, 11]. Importantly, copper is a 
potent prooxidant and excess causes the generation of 
cytotoxic reactive oxygen species (ROS) in cells [9, 
12]. The differential response between normal (healthy) 
and cancerous cells to select copper-ionophores is 
the basis for their development against a variety of 
cancer types, including melanoma and breast cancer 
[13–15]. Nevertheless, the pharmacological mechanism 
responsible for their selective toxicity against cancerous 
cells remains unclear.
Physiological copper interchanges between 
oxidized cupric (CuII) and reduced cuprous (CuI) 
states, enabling it to serve as a rate-limiting cofactor 
for enzymes fundamental for cellular growth and 
development (reviewed in [9]). Cellular acquisition 
and utilization of prooxidant copper is tightly 
regulated by molecular transporters and chaperones 
to prevent deleterious ROS production while satiating 
cuproenzyme metallation [9]. Nevertheless, several 
reports describe copper levels being characteristically 
elevated (2-6 fold) in prostate cancer patient cell lines 
in vitro [7, 16, 17] and in xenograft mouse models [17, 
18], suggesting that patients might harbour elevated 
intratumoral copper. Raised intracellular ROS is a 
well-defined feature of human prostate cancer and 
clinical studies have unequivocally confirmed a role for 
oxidative stress in the development and progression of 
this disease [19–22]. Therefore, it has been postulated 
that elevated endogenous copper may predispose 
prostate cancer cells to copper-ionophore sensitivity, by 
possibly underpinning a heightened state of oxidative 
stress [8, 14, 17, 23]. However, copper ions can exert 
toxicity through a myriad of mechanisms, including 
protein iron-sulfur cluster interference, proteasome 
inhibition and by displacing functional metals 
(e.g. zinc and iron) from metalloproteins [9, 24, 25]. 
Furthermore, we recently established that only a small 
subset of prostate cancer patients actually harbour 
elevated intratumoral copper levels, irrespective of their 
disease stage (Gleason Score 7 or 9) [26]. Therefore, 
clarification on the importance of intratumoral copper 
for the pharmacological activity of copper-ionophores 
is required.
The anticancer activity of bis(thiosemicarbazone) 
copper ligands was established in numerous in vitro and 
in vivo studies mid last century [27–29], originating with the 
demonstration that H2gts [glyoxalbis(thiosemicarbazone)] 
inhibited sarcoma growth in Swiss brown mice [29]. 
We recently established that CuII(gtsm) [glyoxalbis(N4-
methylthiosemicarbazonato)CuII] significantly reduced 
prostate cancer burden (~70%) and severity (lesion grade) in 
the orthotopic TRAMP mouse model [8]. Pharmacokinetic 
analyses in mice confirmed that CuII(gtsm) did not exchange 
coordinated copper with other divalent metals in vivo 
[8]. Mechanistically, CuII(gtsm) undergoes intracellular 
reduction causing copper (CuI) to dissociate into a 
bioavailable (prooxidant) pool. Remarkably, the resultant 
ligand (H2gtsm) continues to re-coordinate and redistribute 
accessible copper [8]. This property renders CuII(gtsm) 
highly toxic toward human prostate cancer cell lines (e.g. 
PC3, DU145, LNCap), while normal cells (e.g. human 
primary prostate epithelial cells) remained refractory [8]. 
The anticancer activity of CuII(gtsm) was copper-dependent, 
positively correlated with milieu copper level and could 
be abrogated with copper chelation [tetrathiomolybdate 
(TTM)] [8]. Stefani and colleagues (2015) more recently 
demonstrated that CuII(gtsm) generates intracellular ROS 
and again validated the requirement for copper for its 
anticancer activity [23]. Two structurally unrelated copper-
ionophores, disulfiram [1-(diethylthiocarbamoyldisulfanyl)-
N,N-diethyl-methanethioamide)] and clioquinol 
(5-chloro-7-iodo-8-quinolinol), likewise display selective 
pharmacological activity against prostate cancer in vitro and 
in mouse models [8, 16, 17]. Analogous to CuII(gtsm), their 
anticancer potency correlated with an intrinsic ability to 
release coordinated copper under the reductive intracellular 
environment [8]. Disulfiram was identified in a screen for 
prostate cancer therapeutics and was subsequently evaluated 
in clinical trials on patients with non-metastatic recurrent 
prostate cancer (500 mg/day) [30]. Disulfiram failed to 
demonstrate clinical activity in these patients, but its 
pharmacokinetics in relation to copper was not evaluated 
and its apo (copper-free) structure was administered. 
Disulfiram, and clioquinol, absolutely require coordinated 
copper for anticancer activity [7, 8]. Another clinical trial 
evaluating disulfiram in the setting of parenteral copper 
supplementation is in the pipeline [17].
Clinical trials of copper-ionophores for prostate 
cancer treatment are clearly outpacing our understanding 
of their mechanism of action. In this study, we aimed to 
delineate the role of elevated intratumoral copper and 
ROS production and establish how copper-ionophores are 
selectively toxic toward prostate cancer cells. Additionally, 
recent in vitro and mouse xenograft studies have suggested 
an increased copper requirement by prostate cancer cells 
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[7, 8, 16-18, 31]. Therefore, we sought to determine the 
importance of copper in prostate cancer development and 
progression in the orthotopic TRAMP mouse model.
RESULTS
Copper homeostasis is maintained during 
prostate cancer progression in TRAMP mice
We previously demonstrated that prostate cancer 
cells in vitro and in the orthotopic TRAMP mouse model 
are highly sensitive to copper-ionophores that increase 
intracellular bioavailable copper [7, 8]. We, and others, 
postulated that endogenous elevated intracellular copper 
predisposed the cancer cells to sensitivity, by possibly 
underpinning a heightened state of oxidative stress [8, 
14, 17, 23]. However, we recently established that only a 
small subset of prostate cancer patients’ harbour elevated 
intratumoral copper [26] and thus sought to clarify 
whether copper is indeed the critical, and targetable, 
factor. To address this question, we surveyed copper levels 
during prostate cancer development in TRAMP mice 
(Figure 1 & 2), having previously obtained significant 
copper-ionophore [CuII(gtsm)] utility in this model [8]. 
Heterozygous male TRAMP mice develop prostate 
adenocarcinoma through the expression of the SV40 large 
T antigen (Tag), which is driven by the prostate epithelial 
specific promoter, probasin. Probasin is androgen-
driven and therefore both Tag expression and cancer 
initiation are developmentally regulated in the mice, 
beginning at 6-weeks of age [32]. Disease development 
in TRAMP mice is well-characterized [8, 32–35], with 
progressive cancer burden monitored by the cumulative 
weight of the genitourinary (GU) tract (includes prostate, 
seminal vesicles, testicles and empty urinary bladder) 
(Figure 1A & 1B). Histological examination of prostate 
lobes [anterior prostate (AP), dorsolateral prostate (DLP) 
and ventral prostate (VP)] with hematoxylin and eosin 
(H&E) staining, verified that prostate cancer develops 
uniformly in the TRAMP mouse model (Figure 1C & 1D); 
initiated with hyperplasia (6-10 weeks), then progressing 
through low-grade prostate intraepithelial neoplasia (PIN) 
(10-14 weeks), high-grade PIN (14-18 weeks), to prostate 
adenocarcinoma (18-22 weeks). The most advanced 
proliferative lesion in each lobe signified the grade of 
disease. Representative images (H&E-stained sections) of 
the various stages of disease severity (grades) can be seen 
in Figure 1D.
Inductively coupled plasma mass spectrometry 
(ICP-MS) was used to establish whether the concentration 
of copper, and of other metals (e.g. zinc and iron), 
changed in the prostate lobes of TRAMP mice during 
disease progression (Figure 2). At no stage during prostate 
cancer development (6, 10, 14, 18 and 22-weeks of age) 
did copper levels fluctuate in comparison to wt mice 
(Figure 2A–2C). These results are analogous to our recent 
findings with human patient prostatectomy samples [26], 
where the vast majority of patients regardless of disease 
severity (Gleason Score 7 or 9) had intratumoral copper 
levels within the normal range. Additionally, serum copper 
level measured across disease progression in TRAMP 
mice did not change (Figure 2D), as likewise noted in 
human prostate cancer patients [26]. In contrast, zinc 
levels were significantly lower in the ventral prostates of 
18 and 22-weeks old TRAMP mice (Figure 2G), which 
is the first prostate lobe where adenocarcinoma arises in 
this model (Figure 1C) [35]. The zinc level in the other 
prostate lobes (anterior and dorsolateral), and in serum, 
did not vary between TRAMP and wt mice at any stage 
(Figure 2E, F & 2H). These findings are consistent with 
those by Costello and colleagues (2004 & 2011), who 
established that as in human prostate cancer, zinc levels 
are markedly decreased in TRAMP adenocarcinomas [33, 
36]. The level of iron in anterior and dorsolateral prostate 
lobes was also significantly reduced in TRAMP mice at 
22 weeks of age (Figure 2I & 2J), consistent with lower 
iron accumulation observed in prostate cancer patients 
compared to healthy subjects [37]. Note that serum iron 
could not be reliably measured due to varying degrees 
of hemolysis between samples, as ruptured erythrocytes 
change iron concentrations (not shown). There were no 
changes to the concentrations of other biologically relevant 
metals, such as selenium and manganese, in prostate 
tissues or serum (not shown). Taken together, these results 
position TRAMP mice as being a clinically relevant 
model to investigate metal homeostasis during prostate 
transformation to malignancy. Moreover, the significant 
copper-ionophore [CuII(gtsm)] utility previously observed 
in this model [8] could not be explained by predisposing 
high intratumoral copper levels.
Copper-ionophores induce oxidative stress in 
TRAMP prostate cancer cells
Three distinct copper-ionophores, CuII(gtsm) 
[bis(thiosemicarbazone) analog], disulfiram (dithiocarbamate 
analog) and clioquinol (hydroxyquinoline analog), all 
release coordinated copper under the reductive intracellular 
environment [8] and display selective anticancer activity in 
vitro and in mouse models (reviewed in [9]). The differential 
response between healthy (normal) and cancerous cells 
to these copper-ionophores is the premise for their further 
development and conceivably, is due to a disparity in handling 
and detoxifying elevated prooxidant copper. To investigate 
this possibility, we compared prostate epithelial cells (PrECs) 
derived from wt mice to cancerous prostate epithelial cells 
(TRAMP-C1) derived from TRAMP mice (Figure 3). 
Prostate tissue used to establish the TRAMP-C1 cell line 
was obtained from a 32-week old TRAMP mouse bearing 
adenocarcinoma, as previously described [38]. The PrEC and 
TRAMP-C1 cell lines had comparable levels of intracellular 
copper (Figure 3A), consistent with our observations using 
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ex vivo prostate tissues derived from wt and TRAMP mice 
(Figure 2A-2C). Nevertheless, TRAMP-C1 cells had 
markedly elevated levels of intracellular ROS (measured 
with H2DCF-DA probe) (Figure 3B), which is a well-defined 
feature in both human [22] and TRAMP prostate cancers 
[39]. Additionally, TRAMP-C1 cells were remarkably more 
sensitive in comparison to prostate epithelial cells (PrECs) 
to copper-ionophore treatments [CuII(gtsm), disulfiram & 
clioquinol] (Figure 3C & 3D), indicating a large therapeutic 
window. Note that the proliferation of PrECs during the 
copper-ionophore treatments was unaffected (not shown). 
These results are consistent with our previous finding using 
human cells, where CuII(gtsm) selectively killed prostate 
hyperplasia and carcinoma cell lines (BPH-1, PC3, DU145 
& LNCaP), while not affecting the viability or proliferation 
of primary prostate epithelial cells [8]. To be consistent with 
our previous studies [7, 8], copper-ionophore treatments were 
in media supplemented with a physiological level in copper 
(20 µM CuCl2). Milieu copper is required for the anticancer 
activities of both disulfiram (DSF) and clioquinol ligands 
[7, 8]. Taken together, these results provide further evidence 
that intracellular copper status does not govern cellular 
sensitivity to copper-ionophores.
To establish if copper-ionophore toxicity correlated 
with oxidative stress, we compared both ROS production 
(Figure 3E) and antioxidant capacity (Figure 3F) between 
the PrEC and TRAMP-C1 cells. Strikingly, copper-
ionophore treatments [CuII(gtsm), disulfiram & clioquinol] 
caused ROS production only in TRAMP-C1 cells 
(Figure 3E[i] & 3[ii]). ROS was measurably elevated after 
6 hours of treatment and was considerably augmented 
after 18 hours of treatment. The same copper-ionophore 
concentrations were associated with TRAMP-C1 cell 
death following 18 hours of treatment (Figure 3C & 3D). 
Glutathione (GSH) is the major cellular antioxidant and 
plays an essential role in protecting cells against ROS 
accumulation and toxicity [40, 41]. An imbalance in 
cellular GSH homeostasis caused by either GSH oxidation 
Figure 1: Prostate cancer develops uniformly in the TRAMP mouse model. A. Progressive cancer burden in TRAMP mice 
monitored by the cumulative weight of the genitourinary (GU) tract (includes prostate, seminal vesicles, testicles and empty urinary 
bladder). GU tracts were weighed from both wild type and TRAMP mice at the indicated ages (6-22 weeks) and normalised to respective 
mouse body weights (n=5-15 at each age). Horizontal black lines represent the mean GU tract weight at the indicated age. B. Representative 
photographs of harvested GU tracts from wild type and TRAMP mice at 10, 18 and 22 weeks of age. C. Histological examination of 
prostate lobes [anterior prostate (AP), dorsolateral prostate (DLP) and ventral prostate (VP)] with hematoxylin and eosin (H&E) staining, 
verifying disease grade in TRAMP mice at the indicated ages (6-22 weeks) (n=5 at each age). The most advanced proliferative lesion 
in each lobe signified the grade of disease. D. Representative H&E-stained sections displaying grades of prostate disease in TRAMP 
mice from hyperplasia, low-grade PIN, high-grade PIN, adenocarcinoma and invasive adenocarcinoma. H&E-stained normal prostate was 
obtained from wild type mice. (***p < 0.001).
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(to GSSG), or by GSH efflux, can diminish the antioxidant 
capacity of the cell and often contributes to cell death [40–
42]. We determined the GSH:GSSG ratio in both PrEC 
and TRAMP-C1 cells, as a well-established marker for 
antioxidant capacity (Figure 3F[iii]) [40, 41]. The basal 
GSH:GSSG ratio was significantly lower in TRAMP-C1 
cells than in PrEC cells (Figure 3F[iii]), meaning that there 
is less protective GSH (Figure 3F[i]) and more oxidized 
GSSG (Figure 3F[ii]) in the cancerous cells. Furthermore, 
sublethal copper-ionophore treatments [CuII(gtsm), 
disulfiram & clioquinol] stimulated an increase in the level 
of protective GSH in PrEC cells (Figure 3G[i]), while in 
stark contrast, caused a reduction in GSH in TRAMP-C1 
cells (Figure 3G[ii]). These results can account for there 
being ROS production observed only in TRAMP-C1 
cells following copper-ionophore treatments (Figure 
Figure 2: Metal levels in prostate tissue and serum during cancer development in TRAMP mice. Inductively coupled 
plasma mass spectrometry (ICP-MS) was used to determine whether copper, zinc or iron concentrations change in prostate lobes and sera of 
TRAMP mice throughout disease progression. A-D. Copper concentrations in anterior prostate (AP), dorso-lateral prostate (DLP), ventral 
prostate (VP) and serum from both wild type and TRAMP mice at the indicated ages (6-22 weeks). Zinc E-H. and iron I-K. concentrations 
are also shown. Results represent mean ± STDEV (bar) and are shown as either µg/g wet weight for tissues (n=5-10 at each age) or µM for 
serum (n=10-17 at each age). (*p < 0.05; ***p < 0.001).
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Figure 3: Copper-ionophores generate intracellular ROS and selectively target TRAMP adenocarcinoma cells 
through a disparity in their antioxidant capacity.  A. TRAMP adenocarcinoma cells (TRAMP-C1) have normal intracellular 
copper levels. Total intracellular copper was measured in both TRAMP-C1 and mouse primary prostate epithelial cells (PrECs) cultured 
under basal conditions. Results are shown as copper (ng) per 106 cells. B. TRAMP adenocarcinoma cells (TRAMP-C1) have elevated 
intracellular ROS levels. Intracellular ROS was measured using the cell permeable fluorogenic probe H2DCF-DA and flow cytometry. 
Results represent mean fluorescence intensity (MFI) (geometric mean). C. Copper-ionophores potently kill TRAMP adenocarcinoma cells 
(TRAMP-C1). TRAMP-C1 cells were treated for 18 hours with CuII(gtsm), disulfiram (DSF) or clioquinol alone or in combination with 
20 μM CuCl2. Ionophore concentrations are shown and cell viability was determined by the propidium iodide exclusion assay and flow 
cytometry. D. Copper-ionophores selectively kill TRAMP adenocarcinoma cells while not affecting the viability of mouse primary prostate 
epithelial cells (PrECs). Both cell lines were treated for 18 hours with CuII(gtsm), disulfiram or clioquinol in combination with 20 μM 
CuCl2. Ionophore concentrations are shown and cell viability was determined by the propidium iodide exclusion assay and flow cytometry. 
E. Copper-ionophores generate intracellular ROS in TRAMP adenocarcinoma cells (TRAMP-C1) (i), but not in mouse primary prostate 
epithelial cells (PrECs) (ii). Both cell lines were treated for 2, 4, 6 or 18 hours with CuII(gtsm), disulfiram or clioquinol in combination 
with 20 μM CuCl2. Ionophore concentrations are shown and intracellular ROS was measured using the cell permeable fluorogenic probe 
H2DCF-DA and flow cytometry. Results represent mean fluorescence intensity (MFI) (geometric mean) F. TRAMP adenocarcinoma cells 
(TRAMP-C1) have markedly reduced antioxidant capacity. Reduced (GSH) (i) and oxidised (GSSG) (ii) glutathione were measured in 
TRAMP adenocarcinoma cells (TRAMP-C1) and mouse primary prostate epithelial cells (PrECs) by HPLC. (iii) The GSH:GSSG ratio is 
compared between both cell lines. G. Differential GSH expression in TRAMP adenocarcinoma cells (TRAMP-C1) treated with copper-
ionophores. Reduced glutathione (GSH) was measured in mouse primary prostate epithelial cells (PrECs) (i) and TRAMP adenocarcinoma 
cells (TRAMP-C1) (ii) following treatment for 18 hours with sublethal concentrations of CuII(gtsm) (20 nM), disulfiram (150 nM) or 
clioquinol (2 µM) (with 20 μM CuCl2). Glutathione (GSH & GSSG) was measured by HPLC. Results represent mean ± STDEV (bar) of 
triplicate determinations for each measurement. (*p < 0.05; **p < 0.01).
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3E[i] & 3E[ii]). Taken together, these data demonstrate 
that adenocarcinoma TRAMP-C1 cells have diminished 
capacity to handle and detoxify auxiliary ROS compared 
to wt prostate epithelial cells (PrECs), providing a premise 
for how copper-ionophores are selective toward prostate 
cancer cells.
Altered systemic copper distribution impedes 
prostate cancer growth
Despite intratumoral copper levels being normal in 
the vast majority of prostate cancer patients [26], and in 
the TRAMP mouse model (Figure 2A,B & 2C), we wanted 
to establish whether copper is nevertheless important 
for prostate cancer growth. However, manipulating diet 
to regulate systemic copper levels in mice is extremely 
difficult, as mice are proficient at maintaining strict 
homeostatic copper levels [12, 43]. Therefore, we decided 
to instead alter copper supply to the prostate by genetically 
modifying copper release from the liver; the central organ 
controlling systemic copper distribution. The toxic milk 
mouse (tx), a well-characterised model for Wilson’s 
disease, has an autosomal recessive mutation in the Atp7b 
gene (A4066G/Met1356Val) that causes substantial 
changes to systemic copper distribution [44, 45]. The gene 
encodes the copper-transporting P-type ATPase expressed 
primarily in the liver (Atp7b), which mediates both 
copper incorporation into serum components (systemic 
distribution) and the excretion of excess copper into 
bile [46]. The tx mutation in Atp7b hinders both of these 
functions [44, 45], therefore we assessed whether it could 
influence prostate cancer growth in the TRAMP mouse 
model (Figure 4 & 5).
The original tx mouse was on the inbred DL strain 
[44, 45, 47, 48], while the tx mice used in this study 
had been backcrossed to the C57BL/6 background for 
10 generations. Therefore, we first verified that our 
tx C57BL/6 model retained the same characteristics 
(Figure 4). Consistently, tx C57BL/6 mice (22-weeks 
old) accumulated substantial levels of hepatic copper 
(~35-fold increase) (Figure 4A) and had elevated 
serum copper content (~1.8-fold increase) (Figure 
4B) [44, 47, 48]. Likewise, TRAMP mice harbouring 
the tx mutation (22-weeks old) had equivalent copper 
manifestations (Figure 4A & 4B). To substantiate 
that copper integration into serum components was 
also perturbed due to the tx mutation, we measured 
ceruloplasmin (CP) oxidase activity (Figure 4C). 
Ceruloplasmin coordinates 6 atoms of allosteric copper 
that are supplied during its biosynthesis by Atp7b (in 
hepatocytes) and accounts for more than 70% of the 
copper found in blood (serum) [9]. Consistent with the 
lack of fully functional Atp7b, mice harbouring the tx 
mutation (tx and tx/TRAMP) had significantly reduced 
serum ceruloplasmin oxidase activity, as measured 
with the conventional o-dianisidine dihydrochloride 
substrate (Figure 4C). A further feature of tx mice is 
copper dyshomeostasis in extrahepatic tissues [47, 48], 
presumably due to the altered serum copper content. 
Elevated copper was found to occur in all extrahepatic 
tissues examined, even those that are not believed 
to express Atp7b [47, 48]. We confirmed that mice 
harbouring the tx mutation (tx and tx/TRAMP) have 
elevated copper in their brain (1.3 to 1.8-fold increase) 
(Figure 4D), kidneys (2-fold increase) (Figure 4E) 
and spleen (7.5 to 12-fold increase) (Figure 4F) and 
further established the same dyshomeostasis in lungs 
(1.4 to 2.2-fold increase) (Figure 4G) and the prostate 
lobes (1.8 to 2.4-fold increase) (Figure 4H[i-iii]). 
Importantly, we demonstrated that normal prostate 
(wtC57BL/6), analogous to most extrahepatic tissues, 
does not express Atp7b at the mRNA (Figure 4I[i]) or 
protein level (Figure 4I[ii]), reducing the possibility of 
a direct influence of the tx mutation on prostate cancer 
growth. Therefore, together these results demonstrate 
that the tx mutation significantly alters systemic copper 
distribution, providing a unique model to explore the 
importance of copper in prostate cancer development 
and progression.
The impact of the tx mutation and associated 
systemic copper misdistribution on prostate cancer 
growth was assessed in 22 and 26-week old male TRAMP 
mice (Figure 5). These ages represent when TRAMP 
mice first develop adenocarcinoma (Figure 1) and 
when considerable prostate cancer growth had occurred 
(Figure 5A), respectively. Notably, there was no difference 
in GU tract weight between tx and wt mice at both 22 
and 26-weeks of age (Figure 5A), demonstrating that the 
tx mutation does not alter normal prostate size. TRAMP 
mice exhibited prostate cancer burden across both age 
groups, with GU tract weights increasing 1.6–fold at 22 
weeks and 2–fold at 26-weeks, when compared to age-
matched wt mice (Figure 5A). Remarkably, TRAMP mice 
harbouring the tx mutation had significantly less prostate 
cancer burden in comparison to the standard TRAMP 
mice. The difference was more pronounced at 26-weeks 
of age, where there was a staggering 64% reduction in 
prostate cancer weight (GU tract weight). Histological 
examination of prostate lobes was further used to establish 
the severity of the proliferative lesions in the 26-week old 
mice, signifying the grade of the disease (Figure 5B). In 
TRAMP mice harbouring the tx mutation there was a 
significant reduction in the severity of prostate lesions in 
both dorsolateral (DLP) and ventral (VP) lobes, with no 
distinguishable adenocarcinoma. Representative images 
(H&E-stained sections) of the mean histological lesion 
seen in each lobe, for both TRAMP and tx harbouring 
TRAMP mice, can be seen in Figure 5C. Together, these 
results demonstrate that altering systemic copper, and 
thus copper supply to the prostate, significantly impedes 
prostate cancer growth and reduces disease severity in 
TRAMP mice.
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Figure 4: The tx mutation in Atp7b substantially alters systemic copper distribution in mice. A&B. TRAMP mice 
harbouring the tx mutation (tx/TRAMP) display elevated copper in their liver and serum. Inductively coupled plasma mass spectrometry 
(ICP-MS) was used to determine copper concentrations in the liver and serum of 22-week old wild type, tx, TRAMP and tx/TRAMP mice 
(n=5-20 for each strain). Results represent mean ± STDEV (whisker plot) and are shown as either µg/g wet weight for tissue or µM for 
serum. C. Copper incorporation into serum ceruloplasmin is perturbed in TRAMP mice harbouring the tx mutation (tx/TRAMP). Serum 
ceruloplasmin oxidase activity (copper-dependent) was measured from 22-week old wild type (n=10), tx (n=11), TRAMP (n=17) and tx/
TRAMP (n=10) mice using the o-dianisidine dihydrochloride based assay. Results are expressed as unit/litre (U/L) and presented as mean 
± STDEV (bar). D-H. TRAMP mice harbouring the tx mutation (tx/TRAMP) display elevated copper in extrahepatic tissues. ICP-MS 
was used to determine copper concentrations in brain, kidney, spleen, lung and prostate lobes [anterior prostate (AP), dorsolateral prostate 
(DLP) and ventral prostate (VP)] of 22-week old wild type, tx, TRAMP and tx/TRAMP mice (n=4-20 for each strain). Results represent 
mean ± STDEV (whisker plot) and are shown as µg/g wet weight. I. Mouse prostate has no detectable level of Atp7b expression. (i) Real-
time PCR quantification of Atp7b mRNA levels in liver (LIV), kidney (KID) and prostate (PRO) of 22-week old wild type mice (n=3). The 
level of Atp7b mRNA is compared against the liver. (ii) Western blot analysis of Atp7b expression in liver (LIV), kidney (KID) and prostate 
(PRO) of 22-week old wild type mice (50 μg protein). The WND4B antibody detected Atp7b in the liver and kidney at ~170kDa. β-actin 
was detected as a loading control. (*p < 0.05; **p < 0.01; ***p < 0.001).
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DISCUSSION
Copper-ionophores are being appraised for a variety 
of therapeutic indications that require a wide range 
of copper-related pharmacological effects. Clioquinol 
analogues (e.g. PBT2) are being trialled in Alzheimer’s 
disease patients, having been shown to dissolve senile 
plaques (pathological hallmark) in mice by redistributing 
copper away from amyloid and into neighbouring 
neurons [49–51]. Similarly, CuII(atsm) [diacetylbis(N4-
methylthiosemicarbazonato)CuII] has proven to be an 
effective treatment for mice with motor neuron disease 
(ALS) [52]. CuII(atsm) releases coordinated copper in 
elevated reductive states [e.g. hypoxic tissues, electron 
transport chain (ETC) compromised cells] [8, 53, 54] and 
corrected superoxide dismutase (SOD) (cuproenzyme) 
levels in copper deficient spinal cords of ALS mice [52, 
54]. Remarkably, ALS mice treated with CuII(atsm) had 
18-months of extended survival [52]. These promising 
studies demonstrate the importance of understanding 
biological and pharmacological activities of copper-
ionophores for their therapeutic purpose. Despite extensive 
study, there is inadequate understanding of how copper-
ionophores function as anticancer agents. In this study, we 
delineated the role of elevated intratumoral copper and 
ROS and provided a premise for how copper-ionophores 
are selectively toxic toward prostate cancer cells.
Prostate tissue copper levels in TRAMP mice 
remained unchanged during prostate cancer development 
and progression (Figure 2A–2D) and thus could not 
explain the significant copper-ionophore [CuII(gtsm)] 
utility previously observed in this model [8]. Cultured 
TRAMP mouse adenocarcinoma cells (TRAMP-C1) 
were likewise susceptible to copper-ionophore treatment 
[CuII(gtsm), disulfiram & clioquinol] (Figure 3C & 3D), 
despite having normal intracellular copper levels when 
Figure 5: Altered systemic copper distribution impedes prostate cancer growth in TRAMP mice. A. The tx mutation 
significantly reduces prostate cancer burden in TRAMP mice. Genitourinary (GU) tracts were weighed from 22-week old and 26-week old 
wild type, tx, TRAMP and tx/TRAMP mice and normalised to respective mouse body weights (n=5-15 for each strain). The mean ± STDEV 
(whisker plot) for each strain is shown. B. The tx mutation significantly reduces prostate cancer disease severity (grade) in TRAMP mice. 
Histological examination of prostate lobes [anterior prostate, dorsolateral prostate and ventral prostate] with hematoxylin and eosin (H&E) 
staining, establishing disease grade in 26-week old wild type, tx, TRAMP and tx/TRAMP mice (n=5 for each strain). The most advanced 
proliferative lesion in each lobe signified the grade of disease. C. Representative H&E-stained sections displaying prostate disease grade in 
the prostate lobes [anterior prostate (AP), dorsolateral prostate (DLP) and ventral prostate (VP)] of 26-week old TRAMP and tx/TRAMP 
mice. (*p < 0.05; **p < 0.01; ***p < 0.001)
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compared to treatment-refractory mouse prostate epithelial 
cells (PrECs) (Figure 3A). These findings are consistent 
with the vast majority of patients with prostate cancer 
(Gleason Score 7 & 9) having intratumoral copper 
levels well within the normal range [26]. Enhanced 
copper uptake by prostate cancer cell lines in vitro and in 
xenografts mouse models, mediated by copper transporter 
1 (hCtr1) protein, elevates intracellular copper and has 
been suggested to underpin copper-ionophore anticancer 
activity [17, 18, 23]. Our results establish that surplus 
copper does not govern the pharmacological facility of 
copper-ionophores, but may heighten clinical activity 
in the small subset of patients found to have elevated 
intratumoral copper [26]. Additionally, surplus copper 
is not required for the altered metabolic requirement of 
prostate cancer. Consistent with malignant transformation 
causing a loss of cell specialization, zinc levels were 
found to be significantly lower following adenocarcinoma 
onset in TRAMP mice (ventral lobe) (Figure 2G) [33, 36]. 
Healthy prostate (includes BPH) contains an extremely 
high concentration of zinc, more than any other soft 
tissue in the body (Figure 2E–2H) [55] and requires 
zinc to change metabolism in order to produce citrate, 
an important component of semen. Prostate cancer 
malignancy necessitates the reduction of intracellular zinc 
to activate mitochondrial aconitase and in turn induce 
citrate oxidation and ATP production (Krebs cycle) [33, 
36, 56]. Accordingly, zinc-ionophores have recently 
emerged as potential therapeutics for prostate cancer [57]. 
Together, copper and zinc levels in TRAMP mice mirror 
those seen in patients with prostate cancer (tissue and 
serum) (Figure 2A–2H) [33, 36, 57], positioning TRAMP 
mice as being clinically relevant to investigate ionophore 
pharmacology.
We demonstrated that TRAMP adenocarcinoma 
cells (TRAMP-C1) have markedly reduced capacity 
to detoxify elevated prooxidant (ionophoric) copper 
(Figure 3E & 3F), providing a basis for their selective 
death in vitro (Figure 3C & 3D) and in mice [8] following 
copper-ionophore treatment. A hallmark of the aggressive 
phenotype of prostate cancer is oxidative stress (increased 
ROS), which has been linked to disease development and 
progression [58–60]. Clinical trials utilizing antioxidants 
have been disappointing (reviewed in [60]), and 
conceivably prooxidant agents (e.g. ionophoric copper) 
used to instead overload the cells with oxidative stress 
may prove more effective. Copper-ionophores [CuII(gtsm), 
disulfiram & clioquinol] that release coordinated copper 
within cells [8] catalysed the formation of intracellular 
ROS in TRAMP adenocarcinoma cells (TRAMP-C1), but 
not in normal prostate epithelial cells (PrECs) at the same 
concentrations (Figure 3E). The anticancer activities of 
CuII(gtsm) and disulfiram have previously been attributed 
to ROS production, as antioxidants (e.g. N-acetyl-L-
cysteine) attenuate their effectiveness [23, 61]. Ordinarily, 
cells have potent antioxidant defence mechanisms and 
one key player, glutathione [reduced (GSH) or oxidised 
(GSSG)], serves as an indicator of the cellular redox status 
[40]. Glutathione (GSH) can directly donate an electron 
(reducing equivalent; H++ e−) to unstable molecules, 
such as ROS. In turn glutathione itself becomes reactive, 
but rapidly bridges (disulfide) with another reactive 
glutathione to form the corresponding disulfide (GSSG). 
Protein glutathionylation can also increase under oxidative 
stress and protects thiols from oxidative modifications 
that can irreversibly alter protein function or stability 
[62]. However, protein glutathionylation is dependent on 
cellular redox status, typically occurring only following 
substantial disruption to the GSH:GSSG ratio [63]. The 
capacity of cells to buffer oxidative stress depends on the 
GSH:GSSG ratio and a reduced intracellular GSH level, 
through oxidation or cellular efflux, has been associated 
with cell death induction [40, 41]. There have been several 
reports that glutathione activity is perturbed in prostate 
cancer [64, 65] and indeed treatment with L-buthionine-
sulfoximine (BSO), an inhibitor of glutathione synthesis, 
potentiates prooxidant (As2O3) toxicity in prostate cancer 
cells [66]. We demonstrated that TRAMP adenocarcinoma 
cells (TRAMP-C1) have markedly elevated ROS (Figure 
3B) coupled with a reduced basal GSH:GSSG ratio that 
corresponded to considerably less protective GSH (~50%) 
(Figure 3F[I]-[III]). Furthermore, copper-ionophore 
[CuII(gtsm), disulfiram & clioquinol] treatments further 
decreased GSH levels in the prostate cancer cells (Figure 
3G[ii]), indicative of exceeding their antioxidant capacity. 
Conversely, identical treatments of normal prostate 
epithelial cells (PrECs) increased their intracellular GSH 
level (Figure 3G[i]), thereby affording protection from 
oxidative stress-induced cell death. Taken together, our 
findings clarify that the anticancer activity of copper-
ionophores is not reliant on intracellular copper level, 
but rather on a disparity in cellular ROS and antioxidant 
capacity.
Wild type mice are proficient at maintaining strict 
homeostatic copper levels and are resistant to copper 
loading through diet [12, 43]. The liver sequesters newly 
absorbed dietary copper and through Atp7b regulates both 
copper incorporation into serum components (systemic 
distribution) and biliary excretion of superfluous copper 
[46]. The tx mutation (Met1356Val) obstructs the copper-
translocation activity of Atp7b [67], causing hepatic copper 
accumulation and altered systemic copper distribution 
[43-45, 47]. The tx mouse is a well-established model 
for the hepatic manifestations seen in Wilson disease and 
exhibits overt liver pathology at around 10-months of 
age [68]. Haplosufficiency necessitates that both Atp7b 
alleles are mutated [43]. An intriguing feature of tx mice is 
copper being systemically elevated in extrahepatic tissues 
(brain, kidney, spleen, lung & prostate) (Figure 4D–4H) 
[43], even in tissues believed not to express Atp7b (lung 
& spleen). We confirmed that mouse prostate does not 
express Atp7b at the mRNA or protein level (Figure 4I). 
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Therefore, the copper dyshomeostasis in extrahepatic 
tissues is seemingly caused by altered copper supply to 
these tissues. Copper distribution to peripheral tissues is 
poorly understood, but circulating ceruloplasmin is known 
to be the major copper-carrying protein (holds >70% of 
serum copper) [9]. The oxidase activity of ceruloplasmin 
requires copper metallation during its biosynthesis, which 
in hepatocytes is mediated by Atp7b [9]. We verified that 
copper integration into serum ceruloplasmin is impeded 
due to the tx mutation (Figure 4C), but nevertheless, tx 
mice harboured elevated serum copper levels (Figure 4B). 
How copper is alternatively incorporated into serum in 
tx mice is part of future investigations. We can confirm 
however, that ceruloplasmin deficiency alone is not 
responsible for the elevated extrahepatic tissue copper 
[69], having shown that ceruloplasmin knockout mice 
have no such copper aberration (Supplementary Figure 
S1). Therefore, the tx mutation more drastically alters 
systemic copper distribution, providing a unique model 
to explore the importance of copper in prostate cancer 
development and progression.
Our study is the first to show that prostate cancer 
growth is reliant on a functional copper supply from 
the liver (Figure 5). TRAMP mice aged to 26-weeks 
harbouring the tx mutation have a remarkable reduction 
in both prostate cancer burden (64% reduction) (Figure 
5A) and disease severity (grade), with no discernable 
carcinoma development (Figure 5B). Copper was 
evidently more important for prostate adenocarcinoma 
development as appose to PIN development (low & 
high-grade), as 22-weeks old TRAMP mice harbouring 
the tx mutation showed less significant disease reduction 
(Figure 5A & 5B). Prostate cancer develops uniformly 
in the TRAMP mouse model, progressing through high-
grade PIN to prostate adenocarcinoma at 18-22 weeks 
of age (Figure 1C). Surplus intratumoral copper is not a 
feature of prostate adenocarcinoma, in both patients (e.g. 
Gleason Score 7 & 9) [26] and TRAMP mice (across all 
grades) (Figure 2A–2C) and is thus not a requirement for 
the altered metabolic needs of aggressive malignancy. 
Instead, collectively our results demonstrate that prostate 
adenocarcinoma development requires the appropriate 
delivery of copper to the prostate gland, through a 
conventional serum carrier(s). Defining the important 
serum copper carrier(s) may provide opportunity to 
pharmacologically exploit this requirement. Moreover, 
understanding the pharmacological effects of complexes 
that target copper (e.g. chelators & ionophores) may 
better tailor their design and in vivo activities, which 
may include altering serum copper distribution. The tx 
mutation by altering serum copper distribution actually 
caused an increase in intratumoral copper in TRAMP 
mice (Figure 4H). Copper is required for numerous 
cuproenzymes involved in cancer progression and 
metastasis [9], however, the surplus intratumoral copper 
caused by altered delivery from the serum did not enhance 
prostate cancer progression. We also cannot rule out the 
possibility that the increased intratumoral copper impeded 
adenocarcinoma development.
In conclusion, we provided evidence that copper-
ionophores can selectively target prostate cancer cells 
through a disparity in their antioxidant capacity and 
therefore are amendable for the treatment of patients 
with prostate cancer. Additionally, elevated intratumoral 
copper was not requisite for their anticancer activity 
and furthermore, was not associated with malignant 
transformation of the prostate in TRAMP mice as 
previously observed in patients [26]. We also demonstrated 
that prostate adenocarcinoma development requires a 
functional supply of copper, being significantly impeded 
by altered systemic copper distribution in mice. Our 
studies warrant further biological and pharmacological 
studies on copper-ionophores, aimed at tailoring their 
activities specifically for prostate cancer therapy.
MATERIALS AND METHODS
Cell culture and reagents
TRAMP-C1 mouse prostate cancer cells were 
derived from the TRAMP (transgenic adenocarcinoma of 
mouse prostate) strain (C57BL/6 background) [38] and 
were generously provided by Assoc. Prof. Michael H. 
Kershaw (Peter MacCallum Cancer Centre, Melbourne, 
Australia). Mouse (C57BL/6) primary prostate epithelial 
cells (PrECs) were purchased from Cell Biologics 
(Chicago, USA; Cat#C57-6038). TRAMP-C1 cells were 
cultured in DMEM (ThermoFisher, Scoresby, Australia; 
Cat#11965-092) supplemented with 10% foetal calf 
serum (Bovogen biologicals, Keilor East, Australia; 
Cat#SFBS-F), 2 mM L-glutamine, 100 Units/mL 
penicillin and 100 μg/mL streptomycin. Primary prostate 
epithelial cells were cultured in Epithelial Cell Medium 
(Cell Biologics, Chicago, USA; Cat# M6621) as per the 
manufacturer’s instructions. Cells were maintained at 
37°C under humidified atmosphere containing 5% CO2.
Copper-ionophores (Disulfiram; Cat#86720 
and clioquinol; Cat#24880) were purchased from 
Sigma-Aldrich (Castle Hill, Australia) or synthesized 
[CuII(gtsm)] by Assoc. Prof. Paul S. Donnelly (University 
of Melbourne, Melbourne, Australia) following published 
procedures [70]. Each copper-ionophore was prepared in 
DMSO at 5 mM immediately before each experiment. All 
other reagents were supplied by Sigma-Aldrich (Castle 
Hill, Australia) unless specified otherwise.
Mouse experiments
Experiments were conducted in accordance 
with national and international guidelines and were 
reviewed and approved by the Deakin University 
Animal Ethics Committee (AEC) (G21/2013 & 
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G01/2014). Homozygous TRAMP mice on the 
C57BL/6 background were maintained as previously 
described [8], while wild type (wt) C57BL/6 mice 
were purchased from the Australian Animal Resources 
Centre (Canning Vale, Australia). Ceruloplasmin (CP) 
knockout C57BL/6 mice and wt littermates were kindly 
provided by Dr. Scott Ayton (University of Melbourne, 
Australia). Heterozygous TRAMP males (referred 
to as TRAMP mice) were generated by crossing 
founder homozygous TRAMP males with wtC57BL/6 
females. Toxic milk mice on the C57BL/6 background 
(referred to as tx mice), containing the A4066G/
Met1356Val mutation in the Atp7b copper-ATPase 
[53], were obtained from Prof. Julian Mercer (Deakin 
University, Burwood, Australia). Several breeding 
steps were required to generate heterozygous TRAMP/
homozygous tx male mice (Tt/XX; where T = Tramp 
& X = tx alleles). Initially, both homozygous mouse 
strains were crossed to produce heterozygous TRAMP/
heterozygous tx progeny (Tt/Xx). The progeny (Tt/Xx) 
were then backcrossed with homozygous tx mice (tt/
XX) to obtain both heterozygous TRAMP/homozygous 
tx male mice (Tt/XX) and homozygous tx male mice 
(tt/XX).
Blood was collected by cardiac puncture and 
incubated on ice for 30 min before serum was isolated by 
two centrifugations at 16,000 g for 5 min and then snap 
frozen. Genitourinary (GU) tracts (includes prostate, 
seminal vesicles, testicles and emptied urinary bladder) 
were removed and their weights normalized against 
respective mouse weights.
Genotyping
The genotypes of all mouse strains were confirmed 
by PCR-based screening using DNA isolated from 
ear tags. The DNA was extracted using the Viagen 
DirectPCR® DNA Extraction System (Viagen, Los 
Angeles, USA; Cat#402-E) with 0.2 mg/mL proteinase 
K. PCR was performed using 2xGo Taq® Hot Start 
Green Master Mix (Promega, Alexandria, Australia; 
Cat#M5122) with the primer sets shown below. 
Presence of the TRAMP SV40 T antigen transgene was 
established using the forward 5’-CCGGTCGACCG
GAAGCTTCCACAAGTGCATTTA-3’ and reverse 
5’-CTCCTTTCAAGACCTAGAAGGTCCA-3’ primers 
as previously described [32]. Primers against mouse 
IL-2 were used as an internal PCR control (forward: 
5’-CTAGGCCACAGAATTGAAAGATCT-3’ and 
reverse: 5’-GTAGGTGGAAATTCTAGCATCATCC-3’). 
Reactions were run on a Biometra PCR machine (Biolabo 
Scientific Instruments, Chatel-St-Denis, Australia) 
using an amplification program of 1 cycle at 94°C for 
5 min, 40 cycles at 94°C for 30 s, 54°C for 30 s, 72°C 
for 1 min and 1 cycle at 72°C for 5 min. Primers used 
to amplify the relevant region of the Atp7b gene, to 
confirm the tx A4066G/Met1356Val mutation, were 
forward 5’-GAGCAGGGCTCTCAGTATTCCCTA
GC-3’ (complementary sequence before exon 19) and 
reverse 5’-GGATACTGAATTCCCATGGTTCAAG-3’ 
(complementary sequence before exon 21). The program 
for amplifying the Atp7b region was 1 cycle at 96°C for 
3 min, 36 cycles at 96°C for 1 min, 55°C for 1 min, 72°C 
for 1 min and 1 cycle at 72°C for 5 min. The resultant 659-
bp PCR product was then digested with NcoI restriction 
endonuclease for 2 hours at 37°C. The attainable NcoI 
profiles included 4 fragments for wtAtp7b (103, 345, 193 
and 18-bp), 3 fragments for the tx mutation (448, 193 
and 18-bp) and 5 fragments for heterozygous mice (103, 
345,448, 193 and 18-bp).
Tissue, serum and intracellular metal analysis
Metal concentrations were determined by 
inductively coupled plasma mass spectrometry (ICP-MS). 
The prostate lobe and other organs [kidney, spleen, lung, 
liver and brain (left hemisphere)] were freeze-dried before 
being digested in 65% nitric acid (50-500 µL) (Suprapur, 
Merck, Bayswater, Australia; Cat#100441) overnight 
at room temperature and then at 90°C for 20 min. An 
equivalent volume of 30% hydrogen peroxide (VWR, 
Tingalpa, Australia; Cat#87003-224) was then added to 
each sample. Samples were incubated 30 min at room 
temperature and 15 min at 70°C and were further diluted 
with 1% nitric acid (900-1000 µl). Serum samples (50 
μL) were diluted in 1% nitric acid (450 μL). Intracellular 
metal analysis of PrEC and TRAMP-C1 cells was 
performed as follows. Cellular pellets were generated as 
previously described [7] and to each pellet 50 μL of 65% 
nitric acid were added and the samples were incubated 
for 6 hours at room temperature before being heated at 
90°C for 20 min. After digestion, 455 μL of 1% nitric acid 
were added to reach a final volume of 500 μL. All metal 
measurements were made using an Agilent 7700 series 
ICPMS instrument under routine multi-element operating 
conditions using a Helium Reaction Gas Cell. The 
instrument was calibrated using 0, 5, 10, 50, 100 and 500 
ppb of certified multi-element ICPMS standard calibration 
solutions (AccuStandard, New Haven, USA; Cat#ICP-
MS-CAL2-1, ICP-MS-CAL-3 & ICP-MS-CAL-4) for a 
range of elements and a certified internal standard solution 
containing 200 ppb of Yttrium (Y89) was used as an 
internal control (AccuStandard; Cat#ICP-MS-IS-MIX1-1). 
The raw ppb values obtained were converted into either 
μg/g of wet weight for tissues (μg/g), to μmol/L for serum, 
or to ng/106 cells for tissue culture as previously described 
[26].
Histological examination
Dissected prostate lobes were fixed in 10% 
neutral buffered formalin overnight at 4°C, before being 
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transferred into 70% ethanol and paraffin-embedded. 
Sections were cut and stained with hematoxylin and 
eosin (H&E). Prostate samples were step sectioned and 
histopathology was determined from at least 6 sections 
per mouse using the TRAMP model scoring system as 
previously described [8]. The most aggressive histological 
lesion observed in each lobe was used to grade each lobe 
and therefore the severity of disease.
Serum ceruloplasmin oxidase activity assay
The oxidase activity of ceruloplasmin in serum was 
measured spectrophotometrically by using o-dianisidine 
dihydrochloride (Sigma-Aldrich, Castle Hill, Australia; 
Cat#D3252) as a substrate, as previously described [71]. 
Briefly, in duplicate 96-well plates 5 μL of sera (or water 
for blank) was added to wells containing 75 μL of 0.1 
M sodium acetate. After a 5 min-incubation at 37˚C, 20 
μL of 7.88 mM o-dianisidine dihydrochloride was then 
added to each well. One plate was incubated for 5 min 
and the other plate for 60 min at 37°C. The reaction was 
then stopped by the addition of 200 μL of 9 M sulphuric 
acid. After 5 min of incubation at room temperature, 
absorbance was read at 540 nm using a multiplate reader 
(Multiskan, ThermoFisher Scientific). Sera from each 
mouse strain (wt, tx, TRAMP & tx/TRAMP) was taken for 
at least 10 individual mice (n=10 to 17) and analysed in 
duplicate. Ceruloplasmin oxidase activity was expressed 
in International Units per litre (U/L) using the following 
formula: (U/L) = (((A60min-A5min)/55))/ε x 1/b x 60 x 1000), 
where A60min and A5min are the absorbance of the 60 min and 
5 min solutions, respectively; ε is the molar absorptivity 
of coloured solutions in terms of substrate consumed (9.6 
mL.μmol-1.cm-1); b = optical length (1 cm); 60 = volume 
correction factor and 1000 = conversion to 1L.
Cell viability and intracellular ROS analysis
Mouse primary prostate epithelial cells (PrECs) 
and TRAMP-C1 cells were seeded (120,000 cells/well) 
separately into 24-well plates and incubated overnight. 
Cells were then treated for 2, 4, 6 or 18 hours in triplicate 
with various concentrations of CuII(gtsm), disulfiram 
(DSF), clioquinol or CuII(atsm) in complete medium with 
or without 20 μM CuCl2. Following treatment, conditioned 
media were collected in 5 mL FACS tubes and adhered 
cells were harvested using 1 mL of trypsin solution 
(0.025% trypsin and 0.02% EDTA) and then combined 
with their corresponding conditioned medium. Cells were 
pelleted by centrifugation at 1,500 rpm for 5 min at 4°C. 
To determine cell viability, cell pellets were resuspended 
in 300 μL of PBS containing 5 μg/mL propidium iodide 
(PI, excitation 538 nm/emission 617 nm) and immediately 
analysed with a FACS Canto II flow cytometer (BD 
Biosciences). 10,000 events were measured and the 
percentage of dead cells (cells positive for PI) was 
determined. To determine intracellular ROS levels 
following treatment, the cells were instead incubated 
in 500 μL of PBS containing 20 μM 2′,7′-dichlorodihy
drofluorescein diacetate (H2DCF-DA) (ThermoFisher 
Scientific, Scoresby, Australia; Cat#D399) for 30 min at 
37°C in the dark. Substrate reaction with ROS results in 
the production of fluorescent dichlorofluorescein (DCF) 
(excitation 495 nm; emission 527 nm). To concurrently 
determine cell viability, PI (2 μg/mL) was added to each 
tube immediately prior to measuring ROS. ROS levels 
were determined by comparing the mean fluorescence 
of treated versus control cells and were expressed as 
percentage of control. 10,000 events were measured and 
only viable cells (negative for PI) were used for analysis. 
Data analysis was performed with BD FACSDiva software 
version 8.0 (BD Biosciences).
GSH and GSSG measurement
GSH and GSSG were measured by HPLC with 
permanganate chemiluminescence detection [72, 73] 
using a GloCel detector with serpentine flow-cell [74]. 
Cell pellets (1 x 106 cells) were homogenised (vortexed) 
in 300 μL of 0.1% formic acid and then centrifuged at 
13000 rpm for 15 min at 4°C. For GSH determination, 
the supernatant was diluted 10-fold in aqueous formic 
acid (5%) immediately prior to analysis. For GSSG 
determination, a second aliquot of supernatant (100 µL) 
was combined with 20 µL of 675 mM Tris-HCl buffer 
(pH 8.0) and 20 µL of 6.3 mM N-ethylmaleimide (NEM) 
to block endogenous GSH, and mixed for 30 s. Then 20 
µL of 8 mM 2-mercaptoethanol was added to react excess 
NEM, and mixed for a further 30 s. To allow for complete 
disulfide bond reduction, 20 µL of 0.78 mM tris(2-
carboxyethyl)phosphine hydrochloride (TCEP) was added 
and the solution gently heated at 50°C for 60 min. Finally, 
20 µL of aqueous formic acid (5%) was introduced to re-
acidify the sample prior to analysis.
Western blot analysis
To detect Atp7b expression in mouse prostate, 
dissected lobes (AP, DLP and VP) were pooled together 
(per mouse) and homogenized as described previously 
[75]. Control organs, including the liver and kidney, 
were similarly prepared. Protein lysates were prepared 
by homogenizing approximately 20 mg of ground liver, 
kidney or prostate tissue, in buffer containing 50 mM Tris, 
150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 
1% Triton-X 100, and complete mini-EDTA free protease 
inhibitor cocktail tablet (Roche Diagnostics GmbH, Castle 
Hill, Australia; Cat#04693124001). Protein samples 
(50 μg) were fractionated on a 7.5% SDS-PAGE and 
transferred to a 0.45 μm nitrocellulose membrane (GE 
Health Care Life Sciences, Australia; Cat#10600002) 
using the Mini Protean Tetra system (BioRad), before 
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being blocked with 5% non-fat dry milk in TBS-T for 
1 hour at room temperature. Mouse Atp7b was detected 
using mWND4B [44] (diluted 1:5,000), followed by HRP-
conjugated donkey anti-goat secondary antibody (Sigma-
Aldrich, Castle Hill, Australia; Cat#A5420) (diluted 
1:5,000). Mouse ceruloplasmin was detected with rabbit 
anti-human ceruloplasmin (Dako, North Sydney, Australia; 
Cat#Q0121)) (diluted 1:1,000), followed by horseradish 
peroxidase-conjugated goat anti-rabbit secondary 
antibody (Dako Cat#P0448) (dilution 1:5,000). Anti-β-
actin antibody (Sigma-Aldrich, Castle Hill, Australia; 
Cat#A5441) (diluted 1:10,000) was used as a loading 
control, with goat anti-mouse HRP secondary antibody 
(Dako; Cat#A5420) (diluted 1:5,000). Bands were 
visualized using Immobilon Western chemiluminescent 
detection kit (Merck Millipore, Bayswater, Australia; 
Cat#WBKLS0500) with the ChemiDoc MP Imaging 
system controlled by ImageLab software version 5.1 
(Bio-Rad).
Real-time quantitative PCR
Tissues were homogenized as previously described 
[75] and total RNA isolated using the Bioline Isolate II 
RNA Mini Kit according to manufacturer’s instructions 
(Bioline, Alexandria, Australia; Cat#BIO-52072). 
cDNA was then synthesized from 1 ug of RNA 
using the SensiFAST cDNA Synthesis Kit (Bioline, 
Alexandria, Australia; Cat#BIO-65053) according to 
manufacturer’s instructions. The specific primers were: 
mouse Atp7b 5’-GAGGGTCCACAGCCCTACAG and 
5’-GCGGGTCCTATTGTCTGAAGTT; and mouse 
GAPDH 5’- TCACCACCATGGAGAAGGC and 5’- 
GCTAAGCAGTTGGTGGTGCA. Real time PCR was 
performed in triplicate on 20 ng of cDNA with the Power 
SYBR-Green PCR Master Mix (ThermoFisher Scientific, 
Scoresby, Australia; Cat#4367659) using the AB 7500 
Real Time PCR System (Applied Biosystems). Primer 
efficiencies were taken into consideration when comparing 
relative amounts of mRNA to the liver using pyQPCR 
Software v0.9.
Statistical analysis
Statistical significance was determined using 
Student t test or multiple t tests (Holm-Sidak method) 
with the GraphPad Prism software (Version 6.05). Unless 
otherwise stated, the data shown are means of at least 
triplicate determinations for each test condition with 
standard deviation (± STDEV).
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